Pretreatment with cyclosporine 0.05% enhances the anti-inflammatory effects of cyclosporine 0.1% in patients with dry eye disease (DED), while pretreatment with either cyclosporine 0.05% or a steroid improves treatment compliance and overall outcomes, according to a study.
The retrospective study compared the effects of cyclosporine 0.1% eye drops in patients with DED following different pretreatment regimens. The study evaluated 274 eyes from 137 patients divided into 3 groups: no pretreatment (Group 1), fluorometholone 0.1% pretreatment (Group 2), and cyclosporine 0.05% pretreatment (Group 3).
Following treatment with cyclosporine 0.1%, DED signs and symptoms improved significantly across all groups. However, Group 3 showed notably greater enhancements in OSDI scores, tear production, and inflammation markers than Groups 1 and 2. Compliance rates were also higher in Groups 2 and 3, with fewer patients discontinuing treatment compared to Group 1.
The findings suggest that pretreatment with cyclosporine 0.05% enhances the anti-inflammatory effects of cyclosporine 0.1%, while pretreatment with either a steroid or a lower cyclosporine concentration improves patient adherence.
Reference
Jee D, Han SY, Kim HS, et al. Comparison of the Effect of and Compliance With Cyclosporine 0.1% After Various Pretreatments in Dry Eye Disease. J Ophthalmol. 2025;2025:6744482. doi: 10.1155/joph/6744482. PMID: 39816208; PMCID: PMC11732286.
Related Content
